Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Vericel's EPS for the twelve months ending Sep 30, 2026 was $0.59, up 210.5% year over year. For fiscal 2025 it was $0.32, up 60.0% from the year before. The highest annual figure on record is $0.32 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0.32 | +60.0% |
| FY2024 | Dec 31, 2024 | $0.20 | – |
| FY2023 | Dec 31, 2023 | -$0.07 | – |
| FY2022 | Dec 31, 2022 | -$0.35 | – |
| FY2021 | Dec 31, 2021 | -$0.16 | -366.7% |
| FY2020 | Dec 31, 2020 | $0.06 | – |
| FY2019 | Dec 31, 2019 | -$0.22 | – |
| FY2018 | Dec 31, 2018 | -$0.20 | – |
| FY2017 | Dec 31, 2017 | -$0.52 | – |
| FY2016 | Dec 31, 2016 | -$1.18 | – |
| FY2015 | Dec 31, 2015 | -$0.97 | – |
| FY2014 | Dec 31, 2014 | -$2.23 | – |
| FY2013 | Dec 31, 2013 | -$6.95 | – |
| FY2012 | Dec 31, 2012 | -$16.25 | – |
| FY2010 | Jun 30, 2010 | -$11.80 | – |
| FY2009 | Jun 30, 2009 | -$18.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $0.27 | +170.0% |
| Q2 FY2026 | Jun 30, 2026 | $0.04 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.12 | – |
| Q4 FY2025 | Dec 31, 2025 | $0.40 | +21.2% |
| Q3 FY2025 | Sep 30, 2025 | $0.10 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.01 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.23 | – |
| Q4 FY2024 | Dec 31, 2024 | $0.33 | +22.2% |
| Q3 FY2024 | Sep 30, 2024 | -$0.02 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.10 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.08 | – |
| Q4 FY2023 | Dec 31, 2023 | $0.27 | +107.7% |
| Q3 FY2023 | Sep 30, 2023 | -$0.08 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.11 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.16 | – |
| Q4 FY2022 | Dec 31, 2022 | $0.13 | +30.0% |
| Q3 FY2022 | Sep 30, 2022 | -$0.14 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.19 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.15 | – |
| Q4 FY2021 | Dec 31, 2021 | $0.10 | -60.0% |
| Q3 FY2021 | Sep 30, 2021 | -$0.11 | -237.5% |
| Q2 FY2021 | Jun 30, 2021 | -$0.08 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.07 | – |
| Q4 FY2020 | Dec 31, 2020 | $0.25 | +25.0% |
| Q3 FY2020 | Sep 30, 2020 | $0.08 | +14.3% |
| Q2 FY2020 | Jun 30, 2020 | -$0.18 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.10 | – |
| Q4 FY2019 | Dec 31, 2019 | $0.20 | +81.8% |
| Q3 FY2019 | Sep 30, 2019 | $0.07 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.45 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.07 | – |
| Q4 FY2018 | Dec 31, 2018 | $0.11 | +1000.0% |
| Q3 FY2018 | Sep 30, 2018 | -$0.02 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.12 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.21 | – |
| Q4 FY2017 | Dec 31, 2017 | $0.01 | 0.0% |
| Q3 FY2017 | Sep 30, 2017 | -$0.16 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.07 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.31 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.01 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?